Department of General and Emergency Surgery, San Filippo Neri Hospital, Rome, Italy.
Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Surg Endosc. 2021 Sep;35(9):4945-4955. doi: 10.1007/s00464-021-08529-4. Epub 2021 May 11.
In right-sided colon cancer surgery, currently there is a great deal of discussion and debate regarding complete mesocolic excision (CME) versus conventional right hemicolectomy (CRH) on postoperative outcomes and oncological results. Our aim was to perform a systematic review of the short- and long-term outcomes of CME to standardize surgical approach in patients with right-sided colon cancer.
A systematic review was performed examining available data on randomized and non-randomized studies evaluating the role of CME and D3 lymphadenectomy in the treatment of right-sided colon cancer, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standards.
After literature search, 919 studies have been recorded, 110 studies underwent full-text reviews and 30 studies met inclusion criteria. The total number of CME procedures was 5931. Postoperative complications was reported in 28 studies with pooled overall complications of 1.88% for CME surgery. Six studies reported 0% of overall postoperative complications and they demonstrated a low incidence of complications following CME procedure. Anastomotic leak was reported in 27 studies with pooled proportion of 0.92% after CME resections. There were 16 papers reporting overall survival following CME procedure, with a mean of 85% of patients survived at 5 years. Mean 5-year overall survival was 93.05% in stage I patients, 89.76% in stage II patients and 79.65% in stage III patients. Local and distant recurrence were included in 21 studies, reporting tumor recurrence rate of 12.25% following CME. 5-year tumor recurrence was 5.8% in stage I patients, 7.68% in stage II patients and 15.69% in stage III patients.
CME does not increase the risk of postoperative complications and significantly improves the long-term oncological impact. Prospective multicentre studies results are needed to verify if CME could be considered standard surgery for right colon cancer.
在右半结肠癌手术中,目前关于完整结肠系膜切除术(CME)与传统右半结肠切除术(CRH)在术后结果和肿瘤学结果方面存在大量讨论和争议。我们的目的是对 CME 的短期和长期结果进行系统评价,以标准化右半结肠癌患者的手术方法。
按照系统评价和荟萃分析的首选报告项目(PRISMA)标准,对评估 CME 和 D3 淋巴结清扫术在右半结肠癌治疗中的作用的随机和非随机研究进行了系统评价。
文献检索后记录了 919 项研究,110 项研究进行了全文审查,30 项研究符合纳入标准。CME 手术总数为 5931 例。28 项研究报告了术后并发症,CME 手术的总体并发症发生率为 1.88%。6 项研究报告了 0%的总体术后并发症,表明 CME 手术后并发症发生率较低。27 项研究报告了吻合口漏,CME 切除术后的总体吻合口漏发生率为 0.92%。有 16 篇论文报告了 CME 手术后的总生存率,5 年生存率平均为 85%。I 期患者的 5 年总生存率为 93.05%,II 期患者为 89.76%,III 期患者为 79.65%。有 21 项研究包括局部和远处复发,报告 CME 后肿瘤复发率为 12.25%。I 期患者的 5 年肿瘤复发率为 5.8%,II 期患者为 7.68%,III 期患者为 15.69%。
CME 不会增加术后并发症的风险,并且显著改善长期肿瘤学影响。需要前瞻性多中心研究结果来验证 CME 是否可被视为右结肠癌的标准手术。